Drug Watch

Latest News

New NDA Submitted: Bysanti to Treat Acute Bipolar I and Schizophrenia

By Leah Kuntz

April 1st 2025

Vanda Pharmaceuticals has submitted an NDA for approval of Bysanti for the treatment of acute bipolar I disorder and schizophrenia.

The Psychiatric Pipeline in Review: Quarter 1, 2025

By Leah Kuntz

March 31st 2025

What percentage of 2025 psychiatric pipeline news was positive vs negative? What disease states are most prominently featured in recent research? Learn more in this exclusive article.

Additional Positive Data on LB-102 for the Treatment of Acutely Exacerbated Schizophrenia

By Leah Kuntz

March 31st 2025

LB Pharmaceuticals presented additional positive data from NOVA1 exploring LB-102 in patients with acutely exacerbated schizophrenia, at the 2025 Annual Congress of the Schizophrenia International Research Society.

Phase 2 Trial Open Enrollment for SPG302, First Synaptic Regenerative Approach to Treat Schizophrenia

By Leah Kuntz

March 31st 2025

Spinogenix announced open enrollment for the phase 2 trial of SPG302, the first synaptic regenerative approach to treat schizophrenia with the potential to improve outcomes across all symptom domains.

Phase 3 Trial Success: Solriamfetol for the Treatment of Adults With ADHD

By Leah Kuntz

March 25th 2025

The FOCUS phase 3 trial of solriamfetol for the treatment of ADHD demonstrated statistically significant improvements in ADHD symptoms and disease severity.

<1 2 3 4 5 6

Do Not Sell My Personal Information

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777